MIF and non-small cell lung carcinoma: Intriguingly, the tumor types that responded best to Imalumab were immune responsive tumors like NSCLC, ovarian, and esophageal-perhaps supporting the possibility that neutralizing MIF therapies may provide immunotherapeutic protections (196).